Analysts Set Expectations for Ocugen FY2025 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Equities researchers at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Ocugen in a report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings per share of ($0.25) for the year. Chardan Capital currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. Chardan Capital also issued estimates for Ocugen’s FY2026 earnings at ($0.27) EPS.

Ocugen (NASDAQ:OCGN) last posted its earnings results on Wednesday, March 5th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. During the same quarter in the previous year, the firm posted ($0.03) EPS.

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Ocugen in a research report on Thursday, March 6th.

Ocugen Stock Performance

Shares of OCGN opened at $0.74 on Thursday. The firm has a market capitalization of $215.80 million, a P/E ratio of -4.11 and a beta of 3.88. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.58 and a quick ratio of 2.58. Ocugen has a one year low of $0.52 and a one year high of $2.08. The business has a fifty day moving average of $0.67 and a 200 day moving average of $0.84.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in OCGN. BNP Paribas Financial Markets bought a new stake in shares of Ocugen during the 4th quarter valued at $30,000. Ameriprise Financial Inc. purchased a new position in Ocugen during the fourth quarter valued at $30,000. Virtu Financial LLC purchased a new position in Ocugen during the fourth quarter valued at $32,000. Tower Research Capital LLC TRC grew its holdings in Ocugen by 309.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company’s stock valued at $32,000 after purchasing an additional 30,120 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new stake in Ocugen in the fourth quarter worth about $40,000. 10.27% of the stock is currently owned by institutional investors.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.